Cameron Stephens Launches Accelerated Lending Program to Support Commercial Real Estate Loans Up To $15 Million
Built to meet the needs of today's market, the Accelerated Lending Program provides single advance inventory, term, bridge, and land loans, with a streamlined commitment process of under 15 days. The initiative targets borrowers who seek faster turnaround times and more flexible structuring outside of conventional lending channels.
All transactions are funded directly through Cameron Stephens' internal mortgage funds—no need for multiple lenders or external syndication. This structure eliminates layers of approval, simplifies deal execution, and significantly reduces time to close.
This new lending channel is powered by up to $500 million in discretionary capital from Cameron Stephens' mortgage funds, including Cameron Stephens Mortgage Trust (CSMT), Bay Street High Yield Fund (BSHY), and Western Canada High Yield Fund (WCHY), providing a direct and streamlined path from capital to borrower.
'We've built this program to move at the speed our borrowers need—no red tape, no delays, just smart capital deployed with precision,' said Steve Cameron, President and COO of Cameron Stephens. 'It's another way we're using our private capital platform to fill market gaps and support our clients through every stage of the real estate development cycle.'
'From a portfolio management perspective, this initiative enhances our ability to dynamically allocate capital across the Cameron Stephens funds,' added Katie Bonar, SVP, Investment Management. 'It allows us to seize short-duration lending opportunities that generate attractive risk-adjusted returns while maintaining the discipline and diversification our investors expect. It's smart capital, well-placed. Within the next six months we anticipate committing in excess of $100 million to this initiative.'
With the Accelerated Lending platform, Cameron Stephens continues to expand its comprehensive suite of commercial real estate lending solutions—combining institutional underwriting with entrepreneurial agility and a simplified, accelerated path to funding.
For more information or to submit a loan inquiry, please contact Katie Bonar, SVP Investment Management, Agent Level 2, at kbonar@cameronstephens.com or call her at 416-899-9701.
About Cameron Stephens
Founded in 2004, Cameron Stephens is a leading Canadian real estate investment firm with nearly $4 billion in assets under administration. Cameron Stephens offers institutional and private investors strategic opportunities to invest in commercial real estate with consistent returns. The firm specializes in mortgage solutions through Cameron Stephens Mortgage Capital for developers across Canada. Established in 2021, Cameron Stephens Equity Capital provides equity opportunities for high-quality and strategically positioned developments.
Leveraging deep market expertise and strong industry partnerships, Cameron Stephens is recognized as a key player in Canada's real estate investment landscape, aiming to deliver sustainable growth and financial success. For more information, visit www.cameronstephens.com.
Cameron Stephens Mortgage Capital Ltd. is licensed as a mortgage brokerage (Lic #10769) and administrator (Lic # 11807) in Ontario.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Great Quest Announces Extension of Final Tranche of Private Placement
VANCOUVER, British Columbia--(BUSINESS WIRE)--Great Quest Gold Ltd. (TSXV:GQ) ('Great Quest' or the 'Company') announces that it has received an extension from the TSX Venture Exchange (the 'Exchange') with respect to the duration of its previously announced non-brokered private placement (the 'Offering'). The outside date upon which final acceptance of the final tranche of the Offering (the 'Final Tranche') will be granted by the Exchange has been extended until August 29, 2025. The Company closed the first tranche of the Offering on July 14, 2025 and issued 11,560,000 common shares (the 'Shares') for gross proceeds of $289,000. The Offering consists of up to 20,000,000 Shares, at a price of $0.025 per Share. All of the Shares issued pursuant to the Offering will be subject to a four month and one day hold period from the date of issue. The Offering is subject to the approval of the Exchange. The net proceeds of the Offering will be used for costs associated with the Company's proposed reverse takeover transaction with Lotus Gold Corporation (the 'Transaction') and general working capital purposes. For further details regarding the Transaction please see the Company's press release dated May 14, 2025. The Company expects to close the Final Tranche on or about August 22, 2025. For further details regarding the Transaction, including the equity ownership that existing Great Quest shareholders will hold in the resulting issuer following completion of the Transaction, please see the Company's press release dated May 14, 2025. About Great Quest Great Quest Gold Ltd. is a Canadian mineral exploration company focused on developing high-potential gold and lithium projects in Namibia, Morocco, and Mali. The Company's flagship asset is the Damara Gold Project in Namibia, which includes the Khorixas, Omatjete, and Outjo projects, covering over 300,000 hectares. Khorixas has yielded high-grade grab samples up to 49.9 g/t Au, while Omatjete and Outjo present significant gold and lithium opportunities. In Mali, Great Quest is advancing the Sanoukou Gold Project, a 24 km 2 concession in the Kayes region. Great Quest Gold Ltd. is listed on the TSX Venture Exchange under the symbol GQ. ON BEHALF OF THE BOARD OF DIRECTORS OF GREAT QUEST GOLD LTD. 'Jed Richardson' Chief Executive Officer and Executive Chairman Disclaimer for Forward-Looking Information This news release may contain forward-looking statements. These statements include statements regarding the Transaction, the Offering and the Final Tranche and use of proceeds and the Company's future plans and objectives. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially because of factors discussed in the management discussion and analysis section of our interim and most recent annual financial statements or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulations. We do not assume any obligation to update any forward-looking statements, except as required by applicable laws. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Business Wire
an hour ago
- Business Wire
CUPE: Air Canada is missing in action at the bargaining table
TORONTO--(BUSINESS WIRE)--With 55 hours to go until Air Canada's lockout notice takes effect, the airline has been absent from the bargaining table for nearly a full day. The union tabled its most recent proposal to Air Canada on August 12 at 9 p.m. ET. The union has been at the bargaining table ever since, waiting for Air Canada to issue their counter-offer. The airline has yet to respond. Needless to say, a negotiation requires two parties to be present, but Air Canada appears to be missing in action. With precious hours to spare before Air Canada's lockout notice takes effect on August 16 at 1:30 a.m. ET, Air Canada owes it to their employees, their passengers, and the Canadian public to take this process seriously. Air Canada should get back to bargaining without delay.
Business Wire
2 hours ago
- Business Wire
Adagio Medical Reports Second Quarter 2025 Results
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ('Adagio' or 'the Company'), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Surpassed 85% enrollment in the FULCRUM-VT pivotal study of the Company's vCLAS™ Cryoablation System. The study, which seeks to enroll 206 patients with either ischemic or non-ischemic drug-refractory, recurrent, sustained monomorphic ventricular tachycardia ('VT') at 20 U.S. and Canadian centers, is on track for completion of patient enrollment in the second half of 2025 First-in-human results from the PARALELL study, which evaluated the safety and effectiveness of Adagio's Pulsed Field Cryoablation ('PFCA'), a novel, dual-energy cardiac ablation modality combining Pulsed Field Ablation (PFA) with Adagio's proprietary Ultra-Low Temperature Cryoablation ('ULTC'), were published in the Journal of Cardiovascular Electrophysiology Reduced cash burn quarter-over-quarter as a result of the Company's corporate prioritization initiative, which streamlined operations and focused resources on highest-value programs 'In the second quarter we saw continued strong momentum in the enrollment of our FULCRUM-VT study, which we believe validates the market need for our purpose-built technology and brings us one step closer to offering our proprietary ULTC solutions to patients in the United States who suffer from ventricular tachycardia,' said Todd Usen, Chief Executive Officer of Adagio. 'The team also made meaningful progress in advancing our pipeline through the continued development of our next-generation product, which is designed to improve usability for physicians while further enhancing the capabilities of our differentiated ULTC platform.' Second Quarter 2025 Financial Results Cost of revenue was $0.3 million for the three months ended June 30, 2025, compared to $0.7 million for the three months ended June 30, 2024. Research and development expenses were $2.0 million for the three months ended June 30, 2025 compared to $2.9 million for the three months ended June 30, 2024 Selling, general and administrative expenses were $2.4 million for the three months ended June 30, 2025, compared to $3.4 million for the three months ended June 30, 2024. Net loss for the three months ended June 30, 2025, was $3.9 million, or $(0.26) per share (Basic), compared to a net loss of $5.7 million, or $(7.35) per share (Basic), for the three months ended June 30, 2024. Reported cash and cash equivalents of $8.2 million as of June 30, 2025. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS™ Cryoablation System, which is CE Marked and is currently under evaluation in the Company's FULCRUM-VT U.S. IDE Pivotal Study. About FULCRUM VT FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm study, enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket approval (PMA) for Adagio's vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT. Adagio's vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic ventricular tachycardia in Europe and select other geographies but is limited to investigational use in the United States. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' 'plans,' and 'future' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning: the potential of Adagio's vCLAS™ Cryoablation System; Adagio's research, development and regulatory plans for its product candidates, including the timing of initiating additional trials and reporting data from its trials; the ability of Adagio to bring its proprietary ULTC solutions to patients in the United States who suffer from VT and their ability to improve usability for physicians; the potential for its product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies; and its current cash resources and the impacts of its corporate prioritization initiative and realignment of resources. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Adagio's business are described in detail in Adagio's Securities and Exchange Commission ('SEC') filings, including in its Annual Report on Form 10-K for the full-year ended December 31, 2024, which is available on the SEC's website at Additional information will be made available in other filings that Adagio makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Adagio disclaims any obligation to update these statements except as may be required by law.
